-
Mashup Score: 0
Bimekizumab initiation resulted in greater or comparable efficacy regarding minimal disease activity and achievement of ACR50/70 compared with guselkumab.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
#Bimekizumab initiation resulted in greater or comparable efficacy regarding minimal disease activity and achievement of ACR50/70 compared with guselkumab. #PsoriaticArthritis https://t.co/qm1wzwUqTd https://t.co/Hz7kJIDeEx